Member Info for RayPointer

We will get to view the event on Proactive's YouTube channel once posted

https://www.proactiveinvestors.co.uk/events

"Watch the event afterwards on our YouTube channel"

Sath is a bit of an all-rounder

https://www.scancell.co.uk/Data/Sites/1/media/publications/rns/230829-scancell-cfo-pr-final.pdf

"Sath earned a BSc in Pharmacology from King’s College,

London, UK and holds an ACA (ICAEW), Chartered Accountant qualification"

He can tell the other panellists all about SCIB1 and then tell them what the price tag is 😂

Perhaps Cliff Holloway set it up to support an upcoming job interview 😀

As posted on a BB for a different company:

https://www.thisismoney.co.uk/money/comment/article-13341575/Dont-let-Nasdaq-aim-AIM-market-says-MAGGIE-PAGANO.html

Rumours are that Nasdaq are interested in buying the AIM market from the London Stock Exchange group.

If such a deal were to go though, it would surely be a good thing for companies such as Scancell.

It sounds like a good incentive to get back on the boat.😀

My take is that this is all smoke and mirrors. As a previous poster noted, this may be the prelude to a placement.

I'm with C11. It's a tenuous connection at best.

Genmab have such a big pipeline and, if they trial products discovered by other companies, they need to do due diligence on the science but also due diligence on the business and patent aspects of any deal.

Judging by the number of views, it looks like Brad's videos have quite a following. Great publicity for Scancell

Remember that CPIs have no memory affect, whereas the T Cells activated by SCIB1 were shown to have a strong memory effect in the first trial.

I'm sure Lindy will expect the same in the Scope trial.

Buying in 311K lots now?.

Absolutely no need to talk about ruck in that manner!

Ear, ear to that 😂

I'm sure it's just a rumour going around, but is it true that inan and ruck have agreed on something?

No mention of it on the BBC website.

I think the deal Lindy wants is on immunobody as a whole, judging by what she said in the 2022 AGM.

So, assuming the SCOPE trial continues to produce results well beyond those produced by the 2 CIs alone (around 50% ORR), it may be well be possible. How such a deal would be structured is anyone's guess and, of course, it takes two to make a deal.

She probably wants to wait until iSCIB1 results are released, since this has the long patent life. So, for SHs, this means a wait until at least the 4th quarter this year and probably beyond this for a possible deal.

Inevitably, if no further glymab deals are done in the meantime, the SP is likely to decline slowly. Bad news for those wanting a quick return this year, but good news for those who have faith in the science and see it as a buying opportunity. However, we may see stunning results for the SCIB1 + 2CIs cohort in Q3. This should re-ignite the interest in SCLP.

Do I get the impression that lofas is not happy?

It's probably best that it's not alive 🚽

Bermuda

I understand perfectly the point you are making. The two trials are different so we are not comparing apples with apples. The measure of 49% improvement over keytruda alone is a measurement that is irrelevant to the Scib1 trial results since keytruda did not figure in this trial.

However, given the fact that scib1 alone gave such outstanding results in the adjuvant setting, must surely be relevant information if and when a pharma is assessing scib1 overall. Surely any prospective partners would be thinking along the lines of conducting a scib1 or iscib1 trial in combination with keytruda trial in the adjuvant setting. This would be in addition to taking the current scope setting into a phase 3 trial.

Bear in mind that there has already been a clinical trial for SCIB1 on it own (i.e. without checkpoint inhibitors) in the adjuvant setting.

The numbers were small in the trial and the delivery method was different to that of the current SCOPE trial.

However, the famous swimchart is testament to the high level of success in this trial, albeit with the limitations stated in the previous sentence.

This will not escape the notice of pharma keeping their eyes on SCIB1 and iSCIB1+ results.

Ruck

Just to remind you

Sheffield United 1 Burnley 4

Bring on Man United next 😀

Ruck

"But I don't think we are privy to enough data to see how 90% confidence was arrived at."

I would guess that Lindy asked someone from the Maths department at Nottingham Uni about the probability of success.

She herself stated that she was informed of the probability but she didn't know how the figure was calculated.

But I do think that SCIB1's chance of success is higher that Burnley's chance of avoiding relegation 😒